دورية أكاديمية
أعرض في EDS

The association of E2F1 and E2F2 single nucleotide polymorphisms with laryngeal squamous cell carcinoma pathomorphological features.

التفاصيل البيبلوغرافية
العنوان: The association of E2F1 and E2F2 single nucleotide polymorphisms with laryngeal squamous cell carcinoma pathomorphological features.
المؤلفون: Jakstas T; Department of Otorhinolaryngology, Lithuanian University of Health Sciences, Kaunas, Lithuania. tomas.jakstas@lsmu.lt., Bartnykaite A; Oncology Research Laboratory, Oncology Institute, Lithuanian University of Health Sciences, Kaunas, Lithuania., Padervinskis E; Department of Otorhinolaryngology, Lithuanian University of Health Sciences, Kaunas, Lithuania., Vegiene A; Department of Otorhinolaryngology, Lithuanian University of Health Sciences, Kaunas, Lithuania., Juozaityte E; Oncology Institute, Lithuanian University of Health Sciences, Kaunas, Lithuania., Uloza V; Department of Otorhinolaryngology, Lithuanian University of Health Sciences, Kaunas, Lithuania., Ugenskiene R; Oncology Research Laboratory, Oncology Institute, Lithuanian University of Health Sciences, Kaunas, Lithuania.; Department of Genetics and Molecular Medicine, Lithuanian University of Health Sciences, Kaunas, Lithuania.
المصدر: BMC cancer [BMC Cancer] 2024 Feb 15; Vol. 24 (1), pp. 214. Date of Electronic Publication: 2024 Feb 15.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: E2F1 Transcription Factor*/genetics , E2F2 Transcription Factor*/genetics , Laryngeal Neoplasms*/genetics , Laryngeal Neoplasms*/pathology , Squamous Cell Carcinoma of Head and Neck*/genetics , Squamous Cell Carcinoma of Head and Neck*/pathology, Humans ; Polymorphism, Single Nucleotide ; Prognosis
مستخلص: Background: Laryngeal squamous cell carcinoma (LSCC) is one of the most common types of cancer in the upper respiratory tract. It is well-known that it has a high mortality rate and poor prognosis in advanced stages. There are well-known risk factors for LSCC, though new specific and prognostic blood-based markers for LSCC development and prognosis are essential. The current study aimed to evaluate the impact of four different single nucleotide polymorphisms (SNPs), E2F1 (rs3213183 and rs3213180) and E2F2 (rs2075993 and rs3820028), on LSCC development, morphological features, and patient 5-year survival rate.
Methods: A total of 200 LSCC patients and 200 controls were included in this study; both groups were matched by age and sex. In the present study, we analyzed four single nucleotide polymorphisms (SNPs) in the genes E2F1 (rs3213183 and rs3213180) and E2F2 (rs2075993 and rs3820028) and evaluated their associations with the risk of LSCC development, its clinical and morphological manifestation, and patients 5-year survival rate. Genotyping was carried out using RT-PCR.
Results: None of the analyzed SNPs showed a direct association with LSCC development. E2F2 rs2075993 G allele carriers (OR = 4.589, 95% CI 1.050-20.051, p = 0.043) and rs3820028 A allele carriers (OR = 4.750, 95% CI 1.088-20.736, p = 0.038) had a statistically significantly higher risk for poor differentiated or undifferentiated LSCC than non-carriers. E2F1 rs3213180 GC heterozygotes were found to have a 3.7-fold increased risk for lymph node involvement (OR = 3.710, 95% CI 1.452-9.479, p = 0.006). There was no statistically significant association between investigated SNPs and patient 5-year survival rate.
Conclusions: The present study indicates that E2F2 rs2075993 and rs3820028 impact LSCC differentiation, whereas E2F1 rs3213180 - on lymph node involvement.
(© 2024. The Author(s).)
References: Cell Death Dis. 2022 Nov 21;13(11):982. (PMID: 36414640)
Int J Ayurveda Res. 2010 Oct;1(4):274-8. (PMID: 21455458)
Am J Cancer Res. 2020 Mar 01;10(3):757-768. (PMID: 32266089)
J Cancer. 2022 Jan 1;13(2):653-668. (PMID: 35069909)
Oral Oncol. 2018 Jun;81:35-44. (PMID: 29884412)
Carcinogenesis. 2021 Nov 12;42(11):1337-1346. (PMID: 34643214)
Aging (Albany NY). 2021 Apr 21;13(10):13626-13643. (PMID: 34091441)
Front Oncol. 2021 Apr 27;11:564296. (PMID: 33987081)
Gene. 2020 Jul 15;747:144700. (PMID: 32330537)
Acta Otorhinolaryngol Ital. 2017 Dec;37(6):458-466. (PMID: 28663597)
Mol Carcinog. 2017 Apr;56(4):1335-1343. (PMID: 27864908)
Int J Cancer. 2022 Aug 15;151(4):553-564. (PMID: 35404482)
Anticancer Res. 2020 Apr;40(4):2003-2009. (PMID: 32234890)
Eur Rev Med Pharmacol Sci. 2017 May;21(9):2150-2156. (PMID: 28537669)
Dis Markers. 2019 Nov 12;2019:3907232. (PMID: 31781300)
BMC Med Genomics. 2023 Feb 28;16(1):38. (PMID: 36855110)
Laryngoscope. 2018 Sep;128(9):2039-2053. (PMID: 29508408)
Eur J Cancer. 2005 Mar;41(5):683-93. (PMID: 15763643)
Immunol Rev. 2008 Dec;226:205-18. (PMID: 19161426)
Laryngoscope. 2008 Dec;118(12):2172-6. (PMID: 19029852)
Int J Mol Sci. 2023 Aug 18;24(16):. (PMID: 37629093)
Oncotarget. 2017 Nov 7;8(66):110635-110649. (PMID: 29299175)
Nat Rev Cancer. 2009 Oct;9(10):738-48. (PMID: 19776743)
Mol Carcinog. 2012 Oct;51 Suppl 1:E132-41. (PMID: 22344756)
CA Cancer J Clin. 2017 Jan;67(1):31-50. (PMID: 27898173)
Rom J Morphol Embryol. 2019;60(2):353-367. (PMID: 31658308)
Cancer Med. 2018 May;7(5):2048-2063. (PMID: 29573243)
Cell Death Dis. 2021 Sep 25;12(10):876. (PMID: 34564711)
Mol Carcinog. 2017 Mar;56(3):1100-1106. (PMID: 27677255)
Cancers (Basel). 2020 Sep 01;12(9):. (PMID: 32882964)
Int J Clin Exp Pathol. 2015 Sep 01;8(9):10545-54. (PMID: 26617764)
Mol Cancer. 2020 Apr 7;19(1):73. (PMID: 32264877)
BMC Cancer. 2014 Mar 14;14:187. (PMID: 24629046)
Cancer Biomark. 2022;34(2):175-188. (PMID: 34719479)
Semin Cancer Biol. 2023 Jul;92:28-41. (PMID: 36924812)
Head Neck. 2018 May;40(5):943-954. (PMID: 29427520)
Laryngoscope. 2017 Jan;127(1):127-133. (PMID: 27392821)
Br J Cancer. 2020 Oct;123(9):1456-1463. (PMID: 32830199)
Pathol Oncol Res. 2023 Apr 24;29:1611123. (PMID: 37168050)
Nat Rev Cancer. 2019 Jun;19(6):326-338. (PMID: 31053804)
ORL J Otorhinolaryngol Relat Spec. 2019;81(2-3):121-129. (PMID: 31067553)
Diagnostics (Basel). 2022 Apr 25;12(5):. (PMID: 35626227)
Int J Med Sci. 2020 Oct 8;17(17):2826-2830. (PMID: 33162810)
J Exp Clin Cancer Res. 2022 Jun 11;41(1):198. (PMID: 35689245)
Med Sci Monit. 2019 Nov 07;25:8389-8402. (PMID: 31698408)
Gene. 2020 Jun 5;742:144589. (PMID: 32179174)
Cancer Manag Res. 2021 Jul 09;13:5509-5521. (PMID: 34276228)
Front Oncol. 2021 May 31;11:655630. (PMID: 34136392)
Otolaryngol Clin North Am. 2008 Aug;41(4):657-72, v. (PMID: 18570952)
Laryngoscope. 2021 Mar;131(3):559-565. (PMID: 32692866)
J Natl Compr Canc Netw. 2020 Jul;18(7):873-898. (PMID: 32634781)
Trends Cell Biol. 2008 Nov;18(11):528-35. (PMID: 18805009)
فهرسة مساهمة: Keywords: E2F1; E2F2; Laryngeal squamous cell carcinoma; SNP
المشرفين على المادة: 0 (E2F1 protein, human)
0 (E2F1 Transcription Factor)
0 (E2F2 protein, human)
0 (E2F2 Transcription Factor)
تواريخ الأحداث: Date Created: 20240215 Date Completed: 20240223 Latest Revision: 20240223
رمز التحديث: 20240223
مُعرف محوري في PubMed: PMC10870611
DOI: 10.1186/s12885-024-11953-z
PMID: 38360622
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-2407
DOI:10.1186/s12885-024-11953-z